Câncer de mama no ASCO 2023 – Parte 2

Notas do episódio

Referências: Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). DOI: 10.1200/JCO.2023.41.17_suppl.LBA1000 Journal of Clinical Oncology 41, no. 17_suppl (June 10, 2023) LBA1000-LBA1000. Published online June 07, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1000?role=tab A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017. DOI: 10.1200/JCO.2023.41.16_suppl.523 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 523-523. Published online May 31, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.523